Back to results
US 2021/0332125 A1Published application
Biopharmaceutical compositions
AssigneeGlaxoSmithKline Intellectual Property (No. 2) Limited
InventorsMyrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
Claims19
A composition comprising an anti-IL-5 antibody having a heavy chain amino acid sequence as shown in SEQ ID NO:
- 1 and a light chain amino acid sequence as shown in SEQ ID NO:
- 2, or an antibody variant having a heavy chain amino acid sequence at least 90% identical to the heavy chain amino acid sequence as shown in SEQ ID NO:
- 1 and/or a light chain amino acid sequence at least 90% identical to the light chain amino acid sequence as shown in SEQ ID NO:
- 2, the composition comprising acidic antibody variants wherein the composition comprises ≤80% acidic antibody variants.
1 more element
Dependencies are inferred from the claim text.